Philogen S.p.A. (BIT: PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.00
0.00 (0.00%)
Sep 4, 2024, 5:35 PM CET
26.51%
Market Cap 846.08M
Revenue (ttm) 24.73M
Net Income (ttm) -6.16M
Shares Out 40.29M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE 20.39
Dividend n/a
Ex-Dividend Date n/a
Volume 1,101
Open 20.80
Previous Close 21.00
Day's Range 20.80 - 21.00
52-Week Range 15.70 - 21.90
Beta 0.19
Analysts n/a
Price Target n/a
Earnings Date Sep 25, 2024

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 165
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.